Sermorelin vs Tesamorelin
Two GHRH-based compounds — one a short fragment, the other a stabilised analog with an FDA approval.
In short: Tesamorelin is a longer, FDA-approved GHRH analog studied specifically for visceral fat; Sermorelin is a shorter diagnostic-origin fragment.
Side-by-side comparison
| Sermorelin | Tesamorelin | |
|---|---|---|
| Class / subtitle | Short-acting GHRH(1-29) analog | FDA-approved stabilised GHRH analog |
| Research status | FDA-approved | FDA-approved |
| Categories | Growth Hormone | Growth Hormone, Weight Loss |
| Primary targets | GHRH receptor | GHRH receptor |
| Half-life | ≈10–20 minutes | ≈26–38 minutes |
| Sequence | GRF(1-29)-NH2 (first 29 residues of human GHRH) | trans-3-hexenoyl-GHRH(1-44) analog |
| Molecular formula | C149H246N44O42S | C221H366N72O67S |
| Molecular weight | 3357.9 g/mol | 5135.9 g/mol |
| CAS number | 86168-78-7 | 218949-48-5 |
| Routes (research) | subcutaneous | subcutaneous |
Sermorelin is a GHRH analog made of the first 29 amino acids of growth-hormone-releasing hormone — the shortest fragment that retains full activity. It was FDA-approved for diagnostic and therapeutic use before being commercially discontinued.
Full Sermorelin profileTesamorelin is a stabilised GHRH analog and the only growth-hormone secretagogue with FDA approval specifically for reducing excess visceral fat (in HIV-associated lipodystrophy).
Full Tesamorelin profileFAQ
What is the main difference between Sermorelin and Tesamorelin?
Tesamorelin is a longer, FDA-approved GHRH analog studied specifically for visceral fat; Sermorelin is a shorter diagnostic-origin fragment.
What is the half-life of Sermorelin compared to Tesamorelin?
Sermorelin: ≈10–20 minutes. Tesamorelin: ≈26–38 minutes.
Provided for research and educational reference only — see ourdisclaimer.